Aclaris Therapeutics (ACRS) Change in Account Payables (2014 - 2026)

Aclaris Therapeutics' Change in Account Payables history runs 13 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• In Q1 2026, Change in Account Payables fell 9.07% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $8.3 million (up 286.18% YoY), while the FY2025 annual figure was $8.4 million, up 301.7% from the prior year.
• Change in Account Payables was $1.5 million for Q1 2026 at Aclaris Therapeutics, down from $4.0 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $4.0 million in Q4 2025 to a low of -$3.5 million in Q2 2024.
• Historically, Change in Account Payables has averaged $274529.4 across 5 years, with a median of $393000.0 in 2024.
• The sharpest annual moves came in 2023 and 2024: Change in Account Payables jumped 233.79% in 2023, then plunged 654.31% in 2024.
• A 5-year view of Change in Account Payables shows it stood at $2.7 million in 2022, then tumbled by 114.66% to -$394000.0 in 2023, then slumped by 654.31% to -$3.0 million in 2024, then jumped by 233.34% to $4.0 million in 2025, then sank by 61.82% to $1.5 million in 2026.
• The last three Change in Account Payables figures came in at $1.5 million (Q1 2026), $4.0 million (Q4 2025), and $377000.0 (Q3 2025), per Business Quant data.